Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
22 09 2020
Historique:
received: 08 05 2020
accepted: 07 08 2020
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 15 5 2021
Statut: ppublish

Résumé

Primary effusion-based lymphoma (EBL) presents as a malignant effusion in a body cavity. The clinicopathologic features and prognosis of primary human herpesvirus 8 (HHV8)-negative EBL remain unclear. We therefore conducted a retrospective study of 95 patients with EBL, regardless of HHV8 status, in Japan. Of 69 patients with EBL tested for HHV8, a total of 64 were negative. The median age of patients with primary HHV8-negative EBL at diagnosis was 77 years (range, 57-98 years); all 58 tested patients were negative for HIV. Primary HHV8-negative EBL was most commonly diagnosed in pleural effusion (77%). Expression of at least 1 pan B-cell antigen (CD19, CD20, or CD79a) was observed in all cases. According to the Hans algorithm, 30 of the 38 evaluated patients had nongerminal center B-cell (non-GCB) tumors. Epstein-Barr virus-encoded small RNA was positive in 6 of 45 patients. In 56 of 64 HHV8-negative patients, systemic therapy was initiated within 3 months after diagnosis. Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimens with or without rituximab (n = 48) were the most common primary treatments. The overall response and complete response rates were 95% and 73%, respectively. Three patients did not progress without systemic treatment for a median of 24 months. With a median 25-month follow-up, the 2-year overall survival and progression-free survival rates were 84.7% and 73.8%. Sixteen patients died; 12 were lymphoma-related deaths. Thus, most EBL cases in Japan are HHV8-negative and affect elderly patients. The non-GCB subtype is predominant. Overall, primary HHV8-negative EBL exhibits a favorable prognosis after anthracycline-based chemotherapy.

Identifiants

pubmed: 32936906
pii: S2473-9529(20)31526-3
doi: 10.1182/bloodadvances.2020002293
pmc: PMC7509864
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4442-4450

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Ann Hematol. 2003 Dec;82(12):773-6
pubmed: 14517692
Hum Pathol. 1997 Jan;28(1):101-4
pubmed: 9013840
J Virol. 2000 Apr;74(8):3478-85
pubmed: 10729121
World J Gastroenterol. 2014 Jan 21;20(3):857-62
pubmed: 24574759
Cancer Genet Cytogenet. 2005 Jan 1;156(1):49-53
pubmed: 15588855
Acta Haematol. 2007;117(3):132-44
pubmed: 17135726
Am J Surg Pathol. 1998 Dec;22(12):1528-37
pubmed: 9850179
Int J Hematol. 2004 Apr;79(3):271-5
pubmed: 15168597
APMIS. 2009 Mar;117(3):222-9
pubmed: 19245595
Blood. 1996 Jul 15;88(2):645-56
pubmed: 8695812
Int J Hematol. 2011 Sep;94(3):279-284
pubmed: 21858447
Acta Haematol. 2013;130(3):217-21
pubmed: 23816805
Int J Hematol. 2001 Oct;74(3):327-32
pubmed: 11721971
Clin Cancer Res. 2007 Sep 1;13(17):5124-32
pubmed: 17785567
Blood. 2015 Jan 1;125(1):22-32
pubmed: 25499448
Am J Hematol. 2004 May;76(1):88-91
pubmed: 15114607
Blood. 1997 Aug 1;90(3):1186-91
pubmed: 9242551
Leuk Lymphoma. 2005 Mar;46(3):415-9
pubmed: 15621832
Semin Cancer Biol. 1999 Jun;9(3):175-85
pubmed: 10343069
Am J Surg Pathol. 2003 Jan;27(1):16-26
pubmed: 12502924
Sci Rep. 2016 Mar 07;6:22730
pubmed: 26947392
Case Rep Oncol Med. 2014;2014:436821
pubmed: 24716045
Blood. 2018 Nov 1;132(18):1879-1888
pubmed: 30154110
Pathol Res Pract. 2015 Dec;211(12):1010-3
pubmed: 26384578
J Clin Oncol. 2011 Oct 10;29(29):e747-50
pubmed: 21810684
Clin Oncol (R Coll Radiol). 2005 Dec;17(8):636-8
pubmed: 16372490
Intern Med. 2008;47(24):2175-8
pubmed: 19075546
Leuk Lymphoma. 2003 Nov;44(11):2019-22
pubmed: 14738159
J Gen Fam Med. 2017 Mar 21;18(1):38-41
pubmed: 29263988
Ann Hematol. 2011 Feb;90(2):219-20
pubmed: 20432036
Int J Hematol. 2018 Sep;108(3):329-334
pubmed: 29516290
Hematol Oncol. 2017 Dec;35(4):878-883
pubmed: 27859456
Syst Rev. 2014 Feb 12;3:11
pubmed: 24521144
Leuk Lymphoma. 2003 Oct;44(10):1811-4
pubmed: 14692539
Lab Med. 2014 Spring;45(2):136-40
pubmed: 24868994
Haematologica. 2008 Jan;93(1):e21-3
pubmed: 18166773
Diagn Cytopathol. 2017 Mar;45(3):257-261
pubmed: 27888664
Histopathology. 2018 May;72(6):930-944
pubmed: 29206290
Intern Med. 2003 Apr;42(4):351-3
pubmed: 12729325
Tuberc Respir Dis (Seoul). 2012 Dec;73(6):336-41
pubmed: 23319997
Leuk Lymphoma. 2002 Mar;43(3):595-601
pubmed: 12002764
Am J Surg Pathol. 2013 Feb;37(2):241-9
pubmed: 23282971
Blood. 2019 Jan 24;133(4):377-380
pubmed: 30510084
BMJ Case Rep. 2012 Jul 13;2012:
pubmed: 22802562
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Intern Med. 2004 Mar;43(3):236-42
pubmed: 15098608
Int J Hematol. 2009 Jul;90(1):94-98
pubmed: 19484335
J Clin Pathol. 2006 Nov;59(11):1221-2
pubmed: 17071811
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
Intern Med. 2010;49(13):1303-6
pubmed: 20606364
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Eur J Haematol. 2003 Jul;71(1):62-7
pubmed: 12801300
Am J Hematol. 2010 Jan;85(1):85-7
pubmed: 20029949
J Med Virol. 1999 Feb;57(2):159-62
pubmed: 9892401
Respir Med Case Rep. 2015 Nov 23;16:169-71
pubmed: 26744692
Curr Top Microbiol Immunol. 2007;312:263-87
pubmed: 17089801
Am J Clin Pathol. 2013 Aug;140(2):258-73
pubmed: 23897264
J Res Med Sci. 2014 Feb;19(2):190-2
pubmed: 24778676
Am J Hematol. 2004 Dec;77(4):419-20
pubmed: 15551361
Ann Hematol. 2014 Sep;93(9):1609-10
pubmed: 24408158
Leuk Lymphoma. 2016 Jul;57(7):1625-32
pubmed: 26727336
Age Ageing. 2006 Jan;35(1):94-6
pubmed: 16364944
J Clin Exp Hematop. 2017;57(2):69-73
pubmed: 29021516
Cancer Res. 1971 Nov;31(11):1860-1
pubmed: 5121694
Cancer. 2016 Sep 1;122(17):2689-97
pubmed: 27337679
Leuk Lymphoma. 2001 Mar;41(1-2):185-9
pubmed: 11342372
Pathol Int. 2001 Apr;51(4):293-300
pubmed: 11350613
Case Rep Oncol Med. 2013;2013:292301
pubmed: 23401819
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Medicine (Baltimore). 2017 Oct;96(43):e8010
pubmed: 29068981
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879

Auteurs

Daisuke Kaji (D)

Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.

Yasunori Ota (Y)

Department of Pathology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Yasuharu Sato (Y)

Department of Pathophysiology, Okayama University Graduate School of Health Sciences, Okayama, Japan.

Koji Nagafuji (K)

Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.

Yasunori Ueda (Y)

Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.

Masataka Okamoto (M)

Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.

Yasushi Terasaki (Y)

Division of Hematology, Toyama City Hospital, Toyama, Japan.

Naoko Tsuyama (N)

Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.

Kosei Matsue (K)

Division of Hematology/Oncology, Department of Medicine, Kameda General Hospital, Chiba, Japan.

Tomohiro Kinoshita (T)

Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Japanese Red Cross Aichi Blood Center, Seto, Japan.

Go Yamamoto (G)

Department of Hematology, Toranomon Hospital, Tokyo, Japan.

Shuichi Taniguchi (S)

Department of Hematology, Toranomon Hospital, Tokyo, Japan.

Shigeru Chiba (S)

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
Department of Hematology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Koichi Ohshima (K)

Department of Pathology, Kurume University School of Medicine, Kurume, Japan; and.

Koji Izutsu (K)

Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH